MCID: BRS047
MIFTS: 100

Breast Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Breast Cancer

MalaCards integrated aliases for Breast Cancer:

Name: Breast Cancer 54 12 25 71 13 52 41 3 14
Breast Carcinoma 12 25 71 29 52 14 69
Breast Cancer, Lobular 54 38 24 29
Male Breast Cancer 12 50 41 14
Malignant Neoplasm of Breast 12 25 69
Breast Cancer, Familial 50 25 69
Malignant Neoplasm of Male Breast 12 69
Invasive Ductal Breast Carcinoma 52 69
Breast Cancer, Invasive Ductal 54 38
Hereditary Breast Carcinoma 50 56
Breast Cancer, Early-Onset 54 29
Familial Breast Carcinoma 50 56
Breast Lobular Carcinoma 12 14
Hereditary Breast Cancer 50 56
Carcinoma of Male Breast 29 69
Breast Cancer, Somatic 54 24
Familial Breast Cancer 50 56
Breast Cancer, Male 54 50
Mammary Carcinoma 12 71
Mammary Cancer 12 25
Mammary Tumor 12 52
Primary Malignant Neoplasm of Breast 69
Breast Cancer, Protection Against 54
Breast Cancer, Susceptibility to 29
Malignant Tumor of the Breast 12
Breast Cancer Susceptibility 54
Breast Cancer, Familial Male 29
Breast Cancer Familial Male 71
Malignant Tumor of Breast 25
Familial Cancer of Breast 29
Animal Mammary Neoplasms 69
Neoplasm of Male Breast 12
Heritable Breast Cancer 50
Breast Cancer Familial 71
Neoplasm of the Breast 29
Breast Neoplasms, Male 42
Primary Breast Cancer 12
Male Breast Carcinoma 50
Genetic Breast Cancer 50
Breast Male Carcinoma 52
Breast Cancer in Men 50
Carcinoma of Breast 12
Mammary Neoplasms 69
Mammary Neoplasm 12
Cancer of Breast 25
Breast Neoplasms 42
Breast Tumor 12
Bc 71

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity


HPO:

32
breast cancer:
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



Summaries for Breast Cancer

NIH Rare Diseases : 50 familial breast cancer is a cluster of breast cancer within a family. most cases of breast cancer occur sporadically in people with little to no family history of the condition. approximately 5-10% of breast cancer is considered "hereditary" and is thought to be caused by an inherited predisposition to breast cancer that is passed down through a family in an autosomal dominant manner. in some of these families, the underlying genetic cause is not known; however, many of these cases are caused by changes (mutations) in the brca1, brca2, pten, tp53, cdh1, or stk11 genes (which are each associated with a unique hereditary cancer syndrome). additional genes, such as chek2, brip1, rad51, and atm, are associated with breast and/or gynecologic cancers in some cases. about 15-20% of women diagnosed with breast cancer have a significant family history of breast cancer (two or more first-degree or second-degree relatives with breast cancer) but have no identifiable mutation in a gene known to cause a hereditary predisposition to breast cancer. these clusters of breast cancer are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.high-risk cancer screening and other preventative measures such as chemoprevention and/or prophylactic surgeries are typically recommended in women who have an increased risk for breast cancer based on their personal and/or family histories. last updated: 8/30/2017

MalaCards based summary : Breast Cancer, also known as breast carcinoma, is related to estrogen-receptor negative breast cancer and progesterone-receptor positive breast cancer, and has symptoms including breast carcinoma, pelvic pain and lameness, animal. An important gene associated with Breast Cancer is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways are Cell Cycle, Mitotic and DNA Double-Strand Break Repair. The drugs Abraxane and Afinitor have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased viability and cellular

UniProtKB/Swiss-Prot : 71 Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

MedlinePlus : 41 breast cancer affects one in eight women during their lives. no one knows why some women get breast cancer, but there are many risk factors. risks that you cannot change include age - the risk rises as you get older genes - two genes, brca1 and brca2, greatly increase the risk. women who have family members with breast or ovarian cancer may wish to be tested for the genes. personal factors - beginning periods before age 12 or going through menopause after age 55 other risks include obesity, using hormone replacement therapy (also called menopausal hormone therapy), taking birth control pills, drinking alcohol, not having children or having your first child after age 35, and having dense breasts. symptoms of breast cancer may include a lump in the breast, a change in size or shape of the breast, and discharge from a nipple. breast self-exams and mammography can help find breast cancer early, when it is most treatable. one possible treatment is surgery. it could be a lumpectomy or a mastectomy. other treatments include radiation therapy, chemotherapy, hormone therapy, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. men can have breast cancer, too, but it is rare. nih: national cancer institute

CDC : 3 Breast cancer is a group of diseases that affects breast tissue. Both women and men can get breast cancer, though it is much more common in women. Other than skin cancer, breast cancer is the most common cancer among women in the United States. Some women are at higher risk for breast cancer than others because of their personal or family medical history or because of certain changes in their genes.

Genetics Home Reference : 25 Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare.

OMIM : 54
Breast cancer (referring to mammary carcinoma, not mammary sarcoma) is histopathologically and almost certainly etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. (114480)

Novus Biologicals : 53 Breast cancer is a malignant tumor that originates from breast tissue cells. Although most breast cancers initiate in the cells that line the breast ducts, some begin in the breast lobules and other tissues. As with all cancers, there is a genetic and environmental component of developing breast cancer. Women with defects in the BRCA1 and BRCA2 genes have up to an 80% chance of getting breast cancer. Research has also found that defects in the ErbB-2 gene lead to increased levels of the protein cyclin D1. Cyclin D1 then activates CDK4, which causes proliferation of cellular division. Blocking CDK4 activity may lead to effective breast cancer treatments.

Disease Ontology : 12 A thoracic cancer that originates in the mammary gland.

Wikipedia : 72 Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in... more...

Related Diseases for Breast Cancer

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ
Brip1-Related Breast Cancer

Diseases related to Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 688)
id Related Disease Score Top Affiliating Genes
1 estrogen-receptor negative breast cancer 35.9 AKT1 BRCA1 BRCA2 CDH1 ESR1 TP53
2 progesterone-receptor positive breast cancer 35.5 AKT1 ESR1 PIK3CA TP53
3 gastric cancer risk after h. pylori infection 33.9 CDH1 KRAS
4 prostate cancer 33.7 AKT1 BRCA1 BRCA2 CDH1 CHEK2 ESR1
5 ductal carcinoma in situ 33.4 BRCA1 BRCA2 CDH1 ESR1 TP53
6 lung cancer 32.5 AKT1 ATM CDH1 KRAS PIK3CA SLC22A18
7 nasopharyngeal carcinoma 32.4 ATM BRCA1 BRCA2 CHEK2 TP53
8 retinal detachment 31.8 BRCA1 BRCA2 ESR1 TP53
9 bacteremia 31.8 BRCA1 BRCA2 PALB2
10 cutaneous lupus erythematosus 31.2 BRCA1 BRCA2
11 systemic lupus erythematosus with nephritis 2 13.0 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
12 exudative vitreoretinopathy 7 12.6 AKT1 BARD1 BRCA1 BRCA2 BRIP1 CDH1
13 brenner tumor of ovary 12.4 ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
14 brenner tumor of the vagina 12.4 ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
15 bilateral breast cancer 12.2
16 cellular myxoid liposarcoma 12.2 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 PALB2
17 childhood ovarian embryonal carcinoma 12.2 ATM BARD1 BRCA1 BRCA2 CHEK2 ESR1
18 trachea squamous cell carcinoma 12.2 AKT1 BRCA1 BRCA2 CDH1 ESR1 KRAS
19 lethal congenital contracture syndrome 10 12.1 AKT1 BRCA1 BRCA2 CDH1 ESR1 KRAS
20 adrenal cortical carcinoma 12.1 AKT1 BRCA1 BRCA2 CDH1 KRAS PALB2
21 dental caries 12.0 AKT1 BRCA1 BRCA2 CDH1 KRAS PIK3CA
22 nasal cavity disease 12.0 AKT1 BRCA1 BRCA2 CDH1 KRAS PIK3CA
23 estrogen-receptor positive breast cancer 12.0
24 breast cancer, childhood 12.0
25 bardet-biedl syndrome 12.0 AKT1 BRCA1 BRCA2 CDH1 ESR1 TP53
26 sporadic breast cancer 12.0
27 amyloid tumor 12.0 ATM BRCA1 BRCA2 CHEK2 PALB2 RAD51
28 mental retardation, autosomal recessive 45 12.0 ATM BRCA1 BRCA2 BRIP1 PALB2 RAD51
29 female breast cancer 11.9
30 mixed cerebral palsy 11.9 ATM BRCA2 ESR1 PALB2 PHB TP53
31 progesterone-receptor negative breast cancer 11.9
32 triple-receptor negative breast cancer 11.9
33 nail disorder, nonsyndromic congenital, 3, 11.9 AKT1 CDH1 CHEK2 KRAS PIK3CA TP53
34 chest wall lymphoma 11.9 ATM BRCA1 BRCA2 ESR1 TP53
35 nail disorder, nonsyndromic congenital, 1 11.9 BRCA1 BRCA2 CDH1 ESR1 TP53
36 inflammatory breast carcinoma 11.9
37 pancreatic somatostatinoma 11.8 AKT1 BRCA2 CDH1 KRAS TP53
38 breast granular cell tumor 11.8 BRCA1 CDH1 ESR1 RAD54L TP53
39 benign shuddering attacks 11.8 AKT1 CDH1 ESR1 KRAS TP53
40 androgen insensitivity, partial, with or without breast cancer 11.8
41 gallbladder cancer 11.8 AKT1 CDH1 KRAS PIK3CA TP53
42 brown-vialetto-van laere syndrome 11.8 AKT1 CDH1 ESR1 KRAS TP53
43 her2-receptor positive breast cancer 11.8
44 her2-receptor negative breast cancer 11.8
45 fallopian tube carcinosarcoma 11.8 BRCA1 BRCA2 ESR1 TP53
46 mycetoma 11.8 BRCA1 BRCA2 TP53 XRCC3
47 anaerobic pneumonia 11.8 BRCA1 CDH1 ESR1 TP53
48 trachea carcinoma in situ 11.7 BRCA1 BRCA2 ESR1 TP53
49 leukemia, acute lymphoblastic 11.7 ATM BRCA1 CHEK2 TP53
50 viral encephalitis 11.7 AKT1 BRCA1 BRCA2 PIK3CA

Graphical network of the top 20 diseases related to Breast Cancer:



Diseases related to Breast Cancer

Symptoms & Phenotypes for Breast Cancer

Symptoms via clinical synopsis from OMIM:

54

Neoplasia:
breast carcinoma


Clinical features from OMIM:

114480

Human phenotypes related to Breast Cancer:

32
id Description HPO Frequency HPO Source Accession
1 breast carcinoma 32 HP:0003002

UMLS symptoms related to Breast Cancer:


pelvic pain, lameness, animal, pain

GenomeRNAi Phenotypes related to Breast Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.85 KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.85 KRAS
3 Decreased viability GR00221-A-1 10.85 KRAS PIK3CA AKT1 ESR1 CDH1
4 Decreased viability GR00221-A-2 10.85 ESR1 KRAS PIK3CA AKT1 BRCA1 CHEK2
5 Decreased viability GR00221-A-3 10.85 AKT1 BRCA1 CHEK2 ATM
6 Decreased viability GR00221-A-4 10.85 PIK3CA AKT1 CHEK2 ESR1 ATM
7 Decreased viability GR00301-A 10.85 KRAS BRCA1 CDH1
8 Decreased viability GR00342-S-2 10.85 CHEK2
9 Decreased viability GR00381-A-1 10.85 KRAS
10 Decreased homologous recombination repair frequency GR00151-A-1 10.79 BARD1 BRCA1 RAD51
11 Decreased homologous recombination repair frequency GR00151-A-2 10.79 BRCA1 RAD51
12 Decreased homologous recombination repair frequency GR00236-A-1 10.79 BARD1 BRCA1 BRCA2 PALB2 RAD51 TSG101
13 Decreased homologous recombination repair frequency GR00236-A-2 10.79 BARD1 BRCA1 BRCA2 PALB2 RAD51 ATM
14 Decreased homologous recombination repair frequency GR00236-A-3 10.79 BARD1 BRCA1 BRCA2 PALB2 RAD51
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.48 BRCA1 PIK3CA
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.48 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 10.48 TSG101
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.48 BRCA1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.48 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.48 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.48 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.48 BRCA1
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.48 BRCA1
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.48 KRAS PIK3CA TSG101
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.48 KRAS
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.48 KRAS
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.48 PHB
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.48 BRCA1 KRAS PHB PIK3CA TSG101
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.48 PIK3CA
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.48 KRAS
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.48 BRCA1
32 Decreased viability in esophageal squamous lineage GR00235-A 10.13 TSG101 BRCA1 BRCA2 CDH1 CHEK2 ESR1
33 Decreased ionizing radiation sensitivity GR00232-A-1 10.03 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
34 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.02 AKT1 RAD54L ATM SLC22A18 BARD1 TP53
35 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.02 ATM SLC22A18 BARD1 TP53 BRCA1 TSG101
36 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.93 ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
37 Decreased viability with cisplatin GR00101-A-4 9.65 BARD1 BRCA1 BRCA2 BRIP1 RAD51
38 Synthetic lethal with cisplatin GR00101-A-1 9.43 BARD1 BRCA1 BRCA2 BRIP1 RAD51 XRCC3

MGI Mouse Phenotypes related to Breast Cancer:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.45 BRCA1 BRCA2 BRIP1 CDH1 CHEK2 ESR1
2 embryo MP:0005380 10.32 AKT1 ATM BARD1 BRCA1 BRCA2 CDH1
3 growth/size/body region MP:0005378 10.32 AKT1 ATM BARD1 BRCA1 BRCA2 CDH1
4 endocrine/exocrine gland MP:0005379 10.31 PIK3CA TP53 TSG101 AKT1 ATM BRCA1
5 homeostasis/metabolism MP:0005376 10.31 AKT1 ATM BRCA1 BRCA2 BRIP1 CDH1
6 mortality/aging MP:0010768 10.28 RB1CC1 TP53 TSG101 XRCC3 AKT1 ATM
7 cardiovascular system MP:0005385 10.24 AKT1 ATM BRCA1 CDH1 ESR1 KRAS
8 immune system MP:0005387 10.22 AKT1 ATM BRCA1 BRCA2 CDH1 CHEK2
9 hematopoietic system MP:0005397 10.2 AKT1 ATM BRCA1 BRCA2 CHEK2 ESR1
10 integument MP:0010771 10.18 AKT1 ATM BRCA1 BRCA2 CDH1 ESR1
11 neoplasm MP:0002006 10.1 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
12 nervous system MP:0003631 9.93 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
13 normal MP:0002873 9.65 BARD1 BRCA1 BRCA2 CDH1 ESR1 KRAS
14 reproductive system MP:0005389 9.36 AKT1 ATM BRCA1 BRCA2 BRIP1 CDH1

Drugs & Therapeutics for Breast Cancer

FDA approved drugs:

(show all 31)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 46 PACLITAXEL Celgene October 2012
2
Afinitor 17 46 EVEROLIMUS Novartis March 2009
3
Aredia 17 46 PAMIDRONATE DISODIUM Chiron August 1996
4
Arimidex 17 46 ANASTROZOLE AstraZeneca January 1996
5
Aromasin Tablets 17 46 EXEMESTANE Pharmacia & Upjohn October 21. 1999
6
CEA-Scan 17 Immunomedics April 1996
7
Ellence 17 46 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
8
Evista 17 46 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
9
Faslodex 17 46 FULVESTRANT AstraZeneca April 2002
10
Femara 17 46 LETROZOLE Novartis January 2001
11
Halaven 17 46 ERIBULIN MESYLATE Eisai November 2010
12
Herceptin 17 46 TRASTUZUMAB Genentech October 1998
13
Ibrance 17 46 PALBOCICLIB Pfizer February 2015
14
Inform HER-2/neu breast cancer test 17 Oncor January 1998
15
Iressa 17 46 GEFITINIB AstraZeneca May 2003
16
Ixempra 17 46 IXABEPILONE Bristol-Myers Squibb October 2007
17
Kadcyla 17 46 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
18
Miraluma Test 17 TECHNETIUM TC-99M SESTAMIBI KIT DuPont Merck Pharmaceutical Company May 1997
19
Neulasta 17 PEGFILGRASTIM Amgen January 2002
20
Neutroval 17 tbo-filgrastim Teva Pharmaceutical August 2012
21
Nolvadex 17 46 TAMOXIFEN CITRATE AstraZeneca October 1998
22
Perjeta 17 46 PERTUZUMAB Genentech June 2012
23
Premarin 17 ESTROGENS CONJUGATED Wyeth July of 2003
24
Self-examination breast pad 17 Inventive Products on December 22, 1995
25
Taxol 17 46 PACLITAXEL Bristol-Myers Squibb August 1997
26
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer May 1996
27
Tykerb 17 46 LAPATINIB DITOSYLATE GlaxoSmithKline March 2007
28
Xeloda 17 46 CAPECITABINE Roche April 1998/ May 2001
29
Xgeva 17 46 DENOSUMAB Amgen June 2013/ November 2010
30
Zoladex 17 46 GOSERELIN ACETATE AstraZeneca January 1996
31
Zometa 17 46 ZOLEDRONIC ACID Novartis August 2001/ February 2002

Drugs for Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1118)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
3
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
4
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
5
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 2,Phase 1 439-14-5 3016
6
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120511-73-1 2187
7
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
8
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10540-29-1 2733526
9
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 180288-69-1 9903
10
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
11
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
12
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
14
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
15
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
16
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2 55-56-1 9552079 2713
17
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
18
Povidone Approved Phase 4,Phase 2 9003-39-8
19 Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
20
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
21
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2180-92-9, 38396-39-3 2474
22
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-43-4 5816
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 437-38-7 3345
24
Ketorolac Approved Phase 4,Phase 3,Phase 2 74103-06-3, 66635-83-4 3826
25
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
26
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 2078-54-8 4943
27 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Early Phase 1
28
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
29
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
30
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
31
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
32
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
33
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
34
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 6740-88-1 3821
35
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
36
Ondansetron Approved Phase 4,Phase 3,Phase 2 99614-02-5 4595
37
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
38
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
39
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
40
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
41
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 865-21-4 13342 241903
42
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 71486-22-1 60780 44424639
43
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
44
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3 10024-97-2 948
45
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
46
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2 28523-86-6 5206
47
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129453-61-8 104741 17756771
48
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 137-58-6 3676
49
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
50
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971

Interventional clinical trials:

(show top 50) (show all 8286)

id Name